Preventing hepatitis B virus reactivation following immunosuppressive therapy

Internal Medicine Journal

Volumn 38, Issue 7, 2008, Pages 617-

  Davis, J ^a,b  

^a ROYAL DARWIN HOSPITAL   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B ANTIGEN; LAMIVUDINE;

ANTIVIRAL THERAPY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; TROPICS; TUBERCULOSIS; VIRUS REACTIVATION;

DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; STEM CELL TRANSPLANTATION;

EID: 48249105475     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01652.x     Document Type: Letter

References (6)

1. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007 37 : 705 12.
2. Davis JS, Currie BJ, Fisher DA, Huffam SE, Anstey NM et al. Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory. Commun Dis Intell 2003 27 : 526 32.
3. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003 125 : 1714 22.
4. Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis Br J Med Virol 2002 66 : 435 51.
5. Buti M, Cotrina M, Jardi R, de Castro EC, Rodriguez-Frias F et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 2001 8 : 270 75.
6. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006 44 : 1656 65.